Angiopoietin–Tie signalling in the cardiovascular and lymphatic systems
|Author:||Eklund, Lauri1; Kangas, Jaakko1; Saharinen, Pipsa2|
1Oulu Center for Cell-Matrix Research, Faculty of Biochemistry and Molecular Medicine, and Biocenter Oulu, Aapistie 5A, FI-90014 Oulu, Finland
2Translational Cancer Biology Program, Research Programs Unit, University of Helsinki, and Wihuri Research Institute, Biomedicum Helsinki, Haartmaninkatu 8, P.O.B. 63, FI-00014 University of Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 0.6 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe201703305880
Portland Press Limited on behalf of the Biochemical Society,
|Publish Date:|| 2017-03-30
Endothelial cells that form the inner layer of blood and lymphatic vessels are important regulators of vascular functions and centrally involved in the pathogenesis of vascular diseases. In addition to the vascular endothelial growth factor (VEGF) receptor pathway, the angiopoietin (Ang)–Tie system is a second endothelial cell specific ligand–receptor signalling system necessary for embryonic cardiovascular and lymphatic development. The Ang–Tie system also regulates postnatal angiogenesis, vessel remodelling, vascular permeability and inflammation to maintain vascular homoeostasis in adult physiology. This system is implicated in numerous diseases where the vasculature has an important contribution, such as cancer, sepsis, diabetes, atherosclerosis and ocular diseases. Furthermore, mutations in the TIE2 signalling pathway cause defects in vascular morphogenesis, resulting in venous malformations and primary congenital glaucoma. Here, we review recent advances in the understanding of the Ang–Tie signalling system, including cross-talk with the vascular endothelial protein tyrosine phosphatase (VE-PTP) and the integrin cell adhesion receptors, focusing on the Ang–Tie system in vascular development and pathogenesis of vascular diseases.
|Pages:||87 - 103|
|Type of Publication:||
A2 Review article in a scientific journal
|Field of Science:||
This work was supported by the Academy of Finland Centre of
Excellence Program [grant numbers 271845 (to P.S.) and 251314
(to L.E.)]; the Academy Research Fellow [grant number 136880 (to
L.E.)]; the Cancer Society of Finland (to PS); and the Sigrid Juselius
Foundation (to PS).
|Academy of Finland Grant Number:||
271845 (Academy of Finland Funding decision)
251314 (Academy of Finland Funding decision)
136880 (Academy of Finland Funding decision)
© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the 97
Creative Commons Attribution Licence 4.0 (CC BY-NC-ND).